Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 8/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.60 |
| ▸ | SYK | P43405 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886268 | 0.77 | SCN9A (0.49) | KCNH2SCN5ASCN9AKDRCDK2 | |
| SCHEMBL2889322 | 0.77 | KCNH2 (0.49) | KCNH2SCN5ASCN9AKDRCDK2 | |
| SCHEMBL2885850 | 0.75 | CDK2 (0.49) | CYP1A2KCNH2SCN5ASCN9AKDR | |
| SCHEMBL13924481 | 0.75 | SYK (0.77) | CYP1A1CYP1A2CYP1B1SYKCDK2 | |
| SCHEMBL28712388 | 0.75 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1ESR1MEN1 | |
| SCHEMBL3130986 | 0.72 | PDPK1 (0.44) | CYP1A1CYP1A2CYP1B1SYKKDR | |
| SCHEMBL13028188 | 0.71 | KDR (0.48) | CYP1A2KCNH2SCN5ASCN9AKDR | |
| SCHEMBL2885798 | 0.71 | CDK2 (0.73) | CYP1A2KCNH2SCN5ASCN9AKDR | |
| SCHEMBL3651665 | 0.70 | CYP1A2 (0.42) | CYP1A1CYP1A2CYP1B1SYKMEN1 | |
| SCHEMBL2891388 | 0.69 | SCN9A (0.50) | CYP1A2KCNH2SCN5ASCN9AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | claimed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | claimed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | claimed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNQ5, KCNA5 | CYP1A1 1961/4885CYP1A2 1246/4885CYP1B1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.